0.05Open0.05Pre Close0 Volume2.18K Open Interest4.00Strike Price0.00Turnover402.55%IV73.82%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1263Delta0.2216Gamma46.60Leverage Ratio-0.0248Theta0.0000Rho5.89Eff Leverage0.0005Vega
Esperion Therapeutics Stock Discussion
money flow is like a lazy cat... what sign is this?
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
No comment yet